» Authors » Gary J Phillips

Gary J Phillips

Explore the profile of Gary J Phillips including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 27
Citations 294
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Hagan A, Znati S, Carter R, Westhorpe A, MacFarlane W, Phillips G, et al.
Anticancer Drugs . 2021 Apr; 32(9):897-908. PMID: 33929994
Vandetanib-eluting radiopaque beads (VERB) have been developed for use in transarterial chemoembolization of liver tumours, with the goal of combining embolization with local delivery of antiangiogenic therapy. The objective of...
2.
Perugini V, Best M, Kumar S, Guildford A, Bone A, MacFarlane W, et al.
J Mater Sci Mater Med . 2018 Jan; 29(1):15. PMID: 29290028
In vitro, pancreatic β-cells tend to reduce their ability to aggregate into islets and lose insulin-producing ability, likely due to insufficient cell-cell and cell-matrix interactions that are essential for β-cell...
3.
Bowyer C, Lewis A, Lloyd A, Phillips G, MacFarlane W
Anticancer Drugs . 2017 May; 28(7):771-780. PMID: 28542038
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer deaths worldwide. The standard of care for intermediate HCC is transarterial chemoembolization, which combines tumour embolization with locoregional delivery...
4.
Ashrafi K, Heaysman C, Phillips G, Lloyd A, Lewis A
Int J Pharm . 2017 Apr; 524(1-2):226-237. PMID: 28373099
Drug release from chemoembolization microspheres stimulated by the presence of a chemically reducing environment may provide benefits for targeting drug resistant and metastatic hypoxic tumours. A water-soluble disulfide-based bifunctional cross-linker...
5.
Hagan A, Phillips G, MacFarlane W, Lloyd A, Czuczman P, Lewis A
Eur J Pharm Sci . 2017 Jan; 101:22-30. PMID: 28132823
Since their introduction around a decade ago, embolic drug-eluting beads (DEBs) have become a well-established treatment option for the locoregional transarterial treatment of hepatic malignancies. Despite this success, the therapy...
6.
Heaysman C, Phillips G, Lloyd A, Lewis A
J Mater Sci Mater Med . 2016 Jan; 27(3):53. PMID: 26787485
To extend the platform of clinically utilised chemoembolic agents based on ion-exchange systems to support the delivery of anionic drugs, a series of PVA-based beads was produced with different levels...
7.
Salvage J, Thom C, Lewis A, Phillips G, Lloyd A
J Mater Sci Mater Med . 2015 Mar; 26(3):150. PMID: 25773229
Biodistribution of nanoparticle-based intracellular delivery systems is mediated primarily by particle size and physicochemical properties. As such, overcoming the rapid removal of these by the reticuloendothelial system remains a significant...
8.
Sandeman S, Howell C, Phillips G, Zheng Y, Standen G, Pletzenauer R, et al.
J Mater Sci Mater Med . 2014 Feb; 25(6):1589-97. PMID: 24573455
Adsorbents designed with porosity which allows the removal of protein bound and high molecular weight uraemic toxins may improve the effectiveness of haemodialysis treatment of chronic kidney disease (CKD). A...
9.
Howell C, Sandeman S, Phillips G, Mikhalovsky S, Tennison S, Rawlinson A, et al.
Int J Artif Organs . 2013 Aug; 36(9):624-32. PMID: 23918264
The aim of the present study was to develop and investigate nanoporous activated carbon materials for their ability to adsorb inflammatory cytokines directly from blood, for a range of therapeutic...
10.
Zheng Y, Gunko V, Howell C, Sandeman S, Phillips G, Kozynchenko O, et al.
ACS Appl Mater Interfaces . 2012 Oct; 4(11):5936-44. PMID: 23088424
A set of glutaraldehyde (GA) cross-linked poly(vinyl alcohol)/activated carbon (PVA/GA/AC) composites prepared in the form of monolithic rods using a cryogelation technique and studied using adsorption, mercury porosimetry, scanning electron...